<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061385</url>
  </required_header>
  <id_info>
    <org_study_id>REDUCE-IDE</org_study_id>
    <nct_id>NCT01061385</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of the ReShape Intragastric Balloon in Obese Subjects</brief_title>
  <official_title>IDE G090121 A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Intragastric Balloon (RIBTM) in Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReShape Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReShape Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluated the safety and efficacy of the ReShape Intragastric Balloon as an adjunct
      to diet and exercise in obese patients compared with diet and exercise alone. The study
      device is designed to occupy space within the stomach and induce satiety. After approval from
      the institutional review board, patients provided written consent and were randomized to the
      treatment group (with endoscopic placement of study device) or the control group (no
      placement of study device) on an unblinded basis. Both groups received similar diet and
      exercise counseling. After 24 weeks, the device was removed. Patient weight, adverse events,
      and quality of life data were evaluated throughout the 48 week study duration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>%Excess Weight Loss</measure>
    <time_frame>36 Weeks</time_frame>
    <description>the difference between the %EWL between treatment and control groups must be clinically significant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With &gt;=25% Excess Weight Loss (EWL)</measure>
    <time_frame>12 months</time_frame>
    <description>a between-group comparison of percentage of treatment subjects achieving &gt;=25% EWL (using the Metropolitan Life Tables (ML) method) compared to the percentage of control group subjects achieving &gt;= 25%EWL at 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>ReShape Intragastric Balloon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving the ReShape Intragastric Balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Weight loss using behavior modification (diet and exercise counseling) alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReShape Intragastric Balloon</intervention_name>
    <description>Placement of ReShape Medical Intragastric Balloon for twenty four weeks</description>
    <arm_group_label>ReShape Intragastric Balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control Arm</intervention_name>
    <description>Behavioral Modification (Diet and exercise counseling) alone</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged ≥ 20 years and ≤ 60 years;

          2. At screening, body mass index (BMI) ≥ 30 Kg/m^2 and ≤ 40 Kg/m^2;

          3. Have a history of obesity (BMI ≥ 30 kg/m^2) for at least 6 months and have failed
             other weight-reduction alternatives, such as supervised diet, exercise and behavioral
             modification programs;

          4. Subject is willing to commit to a long-term low calorie (1000-1500 calories/day)
             supervised diet;

          5. Subject has reasonable weight loss expectations (accept a goal of losing up to 15% of
             body weight after 24 weeks);

          6. At screening, total Beck Depression Inventory (BDI) score &lt; 12 points, and BDI
             affective subscale score &lt; 7 points.

          7. Subject is able to follow requirements outlined in the protocol, including complying
             with the visit schedule, and willing to undergo protocol-specific procedures, e.g.,
             endoscopy, local sedation, general anesthesia, electrocardiography (ECG), and/or
             clinical laboratory testing;

          8. Subject is willing to take prescribed proton pump inhibitors (PPIs);

          9. Subject is able to provide written informed consent;

         10. If female of child-bearing potential, the subject is willing to use contraception
             (e.g., birth control pills, condoms, abstinence) and avoid pregnancy during the study.

        Exclusion Criteria:

          1. Participating in an organized weight loss program (e.g., Weight Watchers);

          2. Parkinson's disease;

          3. Chronic narcotic use;

          4. Clinically relevant abdominal adhesions (e.g., history of bowel obstruction);

          5. History or symptoms of gastrointestinal (GI) surgery (excluding uncomplicated
             appendectomy and cholecystectomy), obstruction, and/or adhesive peritonitis;

          6. History or symptoms of clinically significant esophageal or GI motility disorders;

          7. A hormonal or genetic cause for subject's obesity;

          8. A history of myocardial infarction in the previous 6 months, current New York Heart
             Association (NYHA) Functional Class III or IV (heart failure) or cardiac arrhythmia
             (e.g., atrial fibrillation);

          9. History or symptoms of varices, bowel obstruction, congenital or acquired GI anomalies
             (e.g., atresias, stenosis, stricture, and/or diverticula), severe renal, hepatic,
             and/or pulmonary disease;

         10. History or symptoms of inflammatory bowel disease, such as Crohn's disease;

         11. History or symptoms of uncontrolled or unstable thyroid disease;

         12. Subjects with a positive breath test for Helicobacter pylori at screening;

         13. History or symptoms in the past 12 months of significant irritable bowel disease,
             peritonitis, active esophagitis, gastric or duodenal ulceration, or GI bleeding;

         14. History of esophageal and/or stomach cancer.

         15. Type I diabetes;

         16. Placement of previous intragastric balloon or similar device with associated adverse;
             or any endogastric procedure within the last 6 months;

         17. Ongoing treatment with anticoagulants, steroids, aspirin (&gt; 81 mg/day), non-steroidal
             anti-inflammatory drugs (NSAIDS), or other medications known to be gastric irritants
             or to reduce GI motility, and unwillingness to discontinue the use of these
             concomitant medications;

         18. Concomitant use of prescription, non-prescription, or over-the-counter weight loss
             medications or supplements at any time during the study;

         19. Evidence of untreated psychiatric or eating disorders, such as major depression,
             schizophrenia, substance abuse, binge eating disorder, or bulimia;

         20. Pregnancy, breast feeding, or intention of becoming pregnant during the study (if
             female of childbearing potential);

         21. Known allergy to silicone;

         22. A history of anemia

         23. Participation in another investigational trial within 1 month of screening or planned
             enrollment during the study period.

         24. Presence of peptic ulcerations, hiatal hernia (&gt; 2 cm), patulous pyloric channel,
             erosive esophagitis, varices, angiectasia, Barrett's esophagus or other findings
             deemed exclusionary in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Lou Mooney</last_name>
    <role>Study Director</role>
    <affiliation>ReShape Medical</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <results_first_submitted>August 7, 2015</results_first_submitted>
  <results_first_submitted_qc>November 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 7, 2015</results_first_posted>
  <disposition_first_submitted>June 10, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>June 17, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 25, 2013</disposition_first_posted>
  <last_update_submitted>April 6, 2016</last_update_submitted>
  <last_update_submitted_qc>April 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ReShape Intragastric Balloon</title>
          <description>Patients receiving the ReShape Intragastric Balloon
ReShape Intragastric Balloon: Placement of ReShape Medical Intragastric Balloon for twenty four weeks</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>Patients presenting for weight loss using behaviour modification (diet and exercise) alone.
Behavioral modification: Diet and exercise</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>subject decision not related to AE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants meeting study inclusion/exclusion criteria</population>
      <group_list>
        <group group_id="B1">
          <title>ReShape Intragastric Balloon</title>
          <description>Patients receiving the ReShape Intragastric Balloon
ReShape Intragastric Balloon: Placement of ReShape Medical Intragastric Balloon for twenty four weeks</description>
        </group>
        <group group_id="B2">
          <title>Control Arm</title>
          <description>Patients presenting for weight loss using behaviour modification (diet and exercise) alone.
Behavioral modification: Diet and exercise</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.9" lower_limit="26" upper_limit="59"/>
                    <measurement group_id="B2" value="45.3" lower_limit="37" upper_limit="55"/>
                    <measurement group_id="B3" value="40.8" lower_limit="26" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>%Excess Weight Loss</title>
        <description>the difference between the %EWL between treatment and control groups must be clinically significant</description>
        <time_frame>36 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ReShape Intragastric Balloon</title>
            <description>Patients receiving the ReShape Intragastric Balloon
ReShape Intragastric Balloon: Placement of ReShape Medical Intragastric Balloon for twenty four weeks</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Control subjects receiving diet and exercise counseling only</description>
          </group>
        </group_list>
        <measure>
          <title>%Excess Weight Loss</title>
          <description>the difference between the %EWL between treatment and control groups must be clinically significant</description>
          <units>percent excess weight loss</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="16.7"/>
                    <measurement group_id="O2" value="12.7" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2922</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>21.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With &gt;=25% Excess Weight Loss (EWL)</title>
        <description>a between-group comparison of percentage of treatment subjects achieving &gt;=25% EWL (using the Metropolitan Life Tables (ML) method) compared to the percentage of control group subjects achieving &gt;= 25%EWL at 12 months</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ReShape Intragastric Balloon</title>
            <description>Patients receiving the ReShape Intragastric Balloon
ReShape Intragastric Balloon: Placement of ReShape Medical Intragastric Balloon for twenty four weeks</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Patients presenting for weight loss using behaviour modification (diet and exercise) alone.
Behavioral modification: Diet and exercise</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With &gt;=25% Excess Weight Loss (EWL)</title>
          <description>a between-group comparison of percentage of treatment subjects achieving &gt;=25% EWL (using the Metropolitan Life Tables (ML) method) compared to the percentage of control group subjects achieving &gt;= 25%EWL at 12 months</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.7</ci_lower_limit>
            <ci_upper_limit>38.0</ci_upper_limit>
            <estimate_desc>The 95% CI range above is calculated for the current estimated value.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ReShape Intragastric Balloon</title>
          <description>Patients receiving the ReShape Intragastric Balloon
ReShape Intragastric Balloon: Placement of ReShape Medical Intragastric Balloon for twenty four weeks</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>Patients presenting for weight loss using behaviour modification (diet and exercise) alone.
Behavioral modification: Diet and exercise</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>periorbital edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="25" subjects_affected="18" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>eructation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>abdominal pain upper</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>abdominal discomfort</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>gastric dilatation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>sinus congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hiccups</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI shall furnish a copy of any proposed publication or disclosure at least 60 days prior to submission so that Sponsor may have the opportunity to protect its proprietary rights to information, inventions, or products developed under the Clinical Study. If such publication or disclosure contains Confidential Information, the PI agrees to remove such Confidential Information upon the Sponsor's request.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Given the small sample size of this feasibility cohort, it was not expected to show significant effectiveness.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Director of Clinical Operations</name_or_title>
      <organization>ReShape Medical</organization>
      <phone>949-429-6680</phone>
      <email>lfong@reshapemedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

